Vascular Disrupting Agents Market Key Players Analysis - AGC Biologics (Denmark), Avid Bioservices (US), Bionomics (Australia), Beijing Shenogen Biomedical (China).

Insight Analytics Pvt. Ltd. announces the release of a market assessment report on the "Global Vascular Disrupting Agents Market- by Indications (Chemotherapy-Induced Neutropenia, Glioblastoma, Liver Cancer, Mesothelioma, Non-Small Cell Lung Cancer, Prostate Cancer, Ovarian Cancer, Renal Pelvis and Ureter Cancer), Therapeutic Area (Hematological Malignancies and Solid Tumors), Molecules (Tubulin Binding Agents, Flavonoids and Ligand-Directed Agents), Therapy (Mono and Combination), Route of Administration (Oral and Intravenous), Product (Bavituximab, Icaritin, NGR-TNF, Padeliporfin, Plinabulin, VB-111 and Others), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."

Vascular Disrupting Agents Market Size is predicted to grow at an 10% CAGR during the forecast period for 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1299

Vascular-disrupting agents (VDAs) represent an emerging class of oncology therapeutics designed to selectively target the established neovasculature of tumors while maintaining a favorable toxicity profile. These agents demonstrate minimal overlapping side effects when administered alongside conventional cytotoxic drugs and have shown both synergistic and additive therapeutic effects in combination with widely used chemotherapeutics. Ongoing pharmacological evaluation is essential to determine the most effective drug combinations and interactions between VDAs and other therapeutic classes to optimize clinical outcomes.

The market growth for VDAs is being driven by several key factors, including the rising global incidence of cancer, an expanding geriatric population, and increasing demand for innovative and targeted cancer therapies. Additionally, heightened public awareness of novel treatment options, greater government investment in oncology research and development, the expiration of patents on existing cancer drugs, and shifting lifestyle patterns are further contributing to market expansion. The increasing exposure to cancer risk factors and carcinogenic substances has also led pharmaceutical companies to intensify research efforts, thereby creating new opportunities for the development and commercialization of VDAs. Nonetheless, the high cost associated with targeted therapies and the current lack of comprehensive safety data may pose challenges to broader market adoption in the foreseeable future.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02

North America is anticipated to contribute to the Vascular Disrupting Agents market over the years. The region's growing emphasis on biologics and drug development and the presence of well-established pharmaceutical and biotechnology firms are credited with this increase. The region's rising cancer incidence has also increased the need for tailored treatments. In addition, the Asia Pacific Vascular Disrupting Agents market is expected to grow significantly during the forecast period. Over the projected period, it is anticipated that the region's growth will be aided by robust healthcare infrastructure and rising investment in research and development.

Major market players operating in the Vascular Disrupting Agents market include
AGC Biologics, Avid Bioservices, Bionomics, Beijing Shenogen Biomedical, Mateon Therapeutics, Myrexis, VBL Therapeutics, Steba biotech, BeyondSpring Pharmaceuticals, Immune Pharmaceuticals, Nereus Pharmaceuticals, Madrigal Pharmaceuticals, Inc., Celgene Corporation, Bionomics Ltd., Lees Pharmaceutical Holdings and Other Prominent Players.

Recent collaborations and agreements in the market:
• In December 2021, in response to BeyondSpring Pharmaceuticals' new drug application (NDA) requesting approval of plinabulin coupled with granulocyte colony-stimulating factor (G-CSF) to prevent chemotherapy-induced neutropenia, the US Food and Drug Administration (FDA) sent a complete response letter (CRL) (CIN).
• In June 2021, Updates on the ongoing OVAL Phase 3 study examining ofranergene obadenovec (VB-111) for the treatment of platinum-resistant ovarian cancer were provided by VBL Therapeutics (Israel).

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1299

Market Segments
Global Vascular Disrupting Agents Market, by Indications, 2022-2030 (Value US$ Mn)
• Chemotherapy-Induced Neutropenia
• Glioblastoma
• Liver Cancer
• Mesothelioma
• Non-Small Cell Lung Cancer
• Prostate Cancer
• Ovarian Cancer
• Renal Pelvis
• Ureter Cancer
Global Vascular Disrupting Agents Market, by Therapeutic Area, 2022-2030 (Value US$ Mn)
• Hematological Malignancies
• Solid Tumors
Global Vascular Disrupting Agents Market, by Molecules, 2022-2030 (Value US$ Mn)
• Tubulin Binding Agents
• Flavonoids
• Ligand-Directed Agents
Global Vascular Disrupting Agents Market, by Therapy, 2022-2030 (Value US$ Mn)
• Mono
• Combination
Global Vascular Disrupting Agents Market, by Route of Administration, 2022-2030 (Value US$ Mn)
• Oral
• Intravenous
Global Vascular Disrupting Agents Market, by Product, 2022-2030 (Value US$ Mn)
• Bavituximab
• Icaritin
• NGR-TNF
• Padeliporfin
• Plinabulin
• VB-111
• Others
Global Vascular Disrupting Agents Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Vascular Disrupting Agents Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Vascular Disrupting Agents Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Vascular Disrupting Agents Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Vascular Disrupting Agents Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Vascular Disrupting Agents Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
o Rest of Middle East & Africa

Why should buy this report:
 To receive a comprehensive analysis of the prospects for the global Vascular Disrupting Agents market
 To receive an industry overview and future trends in the Vascular Disrupting Agents market
 To analyze the Vascular Disrupting Agents market drivers and challenges
 To get information on the Vascular Disrupting Agents market value (US$Mn) forecast to 2030
 Significant investments, mergers & acquisitions in the Vascular Disrupting Agents market industry

Read Overview Report- https://www.insightaceanalytic.com/report/global-vascular-disrupting-agents-market/1299

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.